Vipadenant
Vipadenant ( , ; developmental code name BIIB014 and others) is an adenosine A 2A receptor antagonist which was under development for the treatment of Parkinson's disease and cancer but was never marketed.
≈ 1 min read
Names in other languages
No names in other languages are held for this entry yet.
Article bodies are English and are not machine-translated. A name in another language is not a translation of the article.
Vipadenant ( , ; developmental code name BIIB014 and others) is an adenosine A 2A receptor antagonist which was under development for the treatment of Parkinson's disease and cancer but was never marketed. It is taken orally. The drug was first described in the scientific literature by 2006.
It was under development by Vernalis, Biogen, and Juno Therapeutics. Vipadenant reached phase 2 clinical trials prior to the discontinuation of its development.
Text derived from https://en.wikipedia.org/w/index.php?oldid=1360264031 under CC BY-SA 4.0; modifications have been made.